<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39391690</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Prospective proof-of-concept observational RESEarch about traditional herbal preparation Treatment for Chronic Obstructive Pulmonary Disease (RESET-COPD-1).</ArticleTitle><Pagination><StartPage>1437253</StartPage><MedlinePgn>1437253</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1437253</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1437253</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Despite advances in medical science, chronic obstructive pulmonary disease (COPD) continues to impact patients' lives significantly, due to symptom management limitations. Cheongsangboha-tang (CSBHT; Qing Shang Bu Xia Tang) and Hyunggaeyeongyo-tang (HGYGT; Jing Jie Lian Qiao Tang) have been used to treat respiratory diseases, including COPD. However, clinical data supporting their efficacy are lacking. We prospectively observed the response of patients with COPD to CSBHT and HGYGT as adjunctive therapies and assessed the feasibility of future research.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Patients with COPD who were prescribed adjunctive HGYGT or CSBHT according to the COPD clinical practice protocol of Kyung Hee University Korean Medicine Hospital were recruited. Participants visited the hospital every month, for 6 months, to receive herbal preparations according to a Korean Medicine doctor's diagnosis and prescription and outcome evaluations. The primary outcome was the 6-min walking test (6-MWT). Secondary outcomes included the pulmonary function test (PFT), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), and modified Medical Research Council (mMRC) score. Syndrome differentiation, adverse events, and patient adherence were recorded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Thirty-seven patients were initially enrolled and followed up for a mean period of 154.1 days. CSBHT was prescribed to 36 patients, while one patient received either CSBHT or HGYGT, or both, throughout the entire period. During the herbal preparation treatment period, no statistically significant changes were observed in the 6-MWT. The CAT score (mean ± standard deviation) changed from 17.0 ± 5.0 to 12.5 ± 3.6, and the visual analogue scale score for dyspnea changed from 47.5 ± 18.9 to 28.4 ± 18.6 (both statistically significant from visit 5). The coronavirus disease 2019 pandemic precluded the PFT. SGRQ and mMRC scores did not change significantly. During the study period, seven patients dropped out, two experienced mild dyspepsia, and one experienced mild headache. No serious adverse effects were observed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">We illustrated the therapeutic potential of CSBHT and provided preliminary clinical data on its efficacy and safety in patients with COPD. Our study highlights the need to derive optimal herbal formulations, which should be administered for an appropriate duration, based on the therapeutic goals for the treatment of COPD.</AbstractText><CopyrightInformation>Copyright © 2024 Park, Leem, Lee, Kim and Jung.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Park</LastName><ForeName>Dasol</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Diagnostics, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Leem</LastName><ForeName>Jungtae</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Diagnostics, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Korean Medicine Clinical Research Institute, Wonkwang University Korean Medicine Hospital, Iksan, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center of Traditional Korean Medicine, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Beom-Joon</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Korean Medicine, College of Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Allergy, Immune and Respiratory System, Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, Kyung Hee University Medical Center, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kwan-Il</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Department of Clinical Korean Medicine, College of Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Allergy, Immune and Respiratory System, Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, Kyung Hee University Medical Center, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Hee-Jae</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Korean Medicine, College of Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Allergy, Immune and Respiratory System, Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, Kyung Hee University Medical Center, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Qing Shang Bu Xia Tang</Keyword><Keyword MajorTopicYN="N">cheongsangboha-tang</Keyword><Keyword MajorTopicYN="N">chronic obstructive pulmonary disease</Keyword><Keyword MajorTopicYN="N">dyspnea</Keyword><Keyword MajorTopicYN="N">herbal preparation</Keyword><Keyword MajorTopicYN="N">proof-of-concept study</Keyword><Keyword MajorTopicYN="N">prospective observational study</Keyword><Keyword MajorTopicYN="N">respiratory disease</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>4</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39391690</ArticleId><ArticleId IdType="pmc">PMC11464318</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1437253</ArticleId><ArticleId IdType="pii">1437253</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adeloye D., Chua S., Lee C., Basquill C., Papana A., Theodoratou E., et al. (2015). Global and regional estimates of COPD prevalence: systematic review and meta–analysis. J. Glob. Health 5, 020415. 10.7189/jogh.05-020415</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.05-020415</ArticleId><ArticleId IdType="pmc">PMC4693508</ArticleId><ArticleId IdType="pubmed">26755942</ArticleId></ArticleIdList></Reference><Reference><Citation>ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002). ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 166, 111–117. 10.1164/ajrccm.166.1.at1102</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.166.1.at1102</ArticleId><ArticleId IdType="pubmed">12091180</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek H., Bhang Y., Kim J., Kim S.-J., Kim K., Lee B., et al. (2016a). A retrospective study of chronic pulmonary disease patients treated with chungsangboha-tang: IgE, eosinophil, PFT. J. Korean Orient. Intern. Med. 37, 484–494.</Citation></Reference><Reference><Citation>Baek H., Lee B., Jung S., Jung H. (2016b). Retrospective study of patients with cough treated with eunhwayeongyo-tang. J. Int. Korean Med. 37, 961–977. 10.22246/jikm.2016.37.6.961</Citation><ArticleIdList><ArticleId IdType="doi">10.22246/jikm.2016.37.6.961</ArticleId></ArticleIdList></Reference><Reference><Citation>
Bang J. H., Jae J. H., Jung S. K. (2011). A clinical observation of chungsangboha-tang’s effects on asthmatic patients. J. Korean Orient. Intern. Med.
32, 10–25. Available at: https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001543582.
</Citation></Reference><Reference><Citation>Brandsma C.-A., Van den Berge M., Hackett T.-L., Brusselle G., Timens W. (2020). Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine. J. Pathol. 250, 624–635. 10.1002/path.5364</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5364</ArticleId><ArticleId IdType="pmc">PMC7216938</ArticleId><ArticleId IdType="pubmed">31691283</ArticleId></ArticleIdList></Reference><Reference><Citation>
Brunson J. C. (2020). ggalluvial: alluvial Plots in “ggplot2”. R. package. Available at: http://corybrunson.github.io/ggalluvial/.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10010671</ArticleId><ArticleId IdType="pubmed">36919162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X., Wang Y., Chen Y., Zhao M., Liang L., Yang M., et al. (2023). Advances in traditional Chinese medicine for the treatment of chronic obstructive pulmonary disease. J. Ethnopharmacol. 307, 116229. 10.1016/j.jep.2023.116229</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2023.116229</ArticleId><ArticleId IdType="pubmed">36773789</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaillès A., Brinchault-Rabin G., Dixmier A., Goupil F., Gut-Gobert C., Marchand-Adam S., et al. (2013). Comorbidities of COPD. Eur. Respir. Rev. 22, 454–475. 10.1183/09059180.00008612</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09059180.00008612</ArticleId><ArticleId IdType="pmc">PMC9639181</ArticleId><ArticleId IdType="pubmed">24293462</ArticleId></ArticleIdList></Reference><Reference><Citation>Corlateanu A., Plahotniuc A., Corlateanu O., Botnaru V., Bikov A., Mathioudakis A. G., et al. (2021). Multidimensional indices in the assessment of chronic obstructive pulmonary disease. Respir. Med. 185, 106519. 10.1016/j.rmed.2021.106519</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2021.106519</ArticleId><ArticleId IdType="pubmed">34175803</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng C.-N., Hu H.-Y., Ji Z.-C., Qiang X.-Y., Chen Z., Ou Y., et al. (2022). Clinical trials and evaluation of Chinese patent medicine for chronic obstructive pulmonary disease. Zhongguo Zhong Yao Za Zhi 47, 2351–2357. 10.19540/j.cnki.cjcmm.20210910.501</Citation><ArticleIdList><ArticleId IdType="doi">10.19540/j.cnki.cjcmm.20210910.501</ArticleId><ArticleId IdType="pubmed">35531683</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo J., Landis S. H., Maskell J., Oh Y.-M., van der Molen T., Han M. K., et al. (2016). Continuing to confront COPD international patient survey: economic impact of COPD in 12 countries. PLoS One 11, e0152618. 10.1371/journal.pone.0152618</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0152618</ArticleId><ArticleId IdType="pmc">PMC4836731</ArticleId><ArticleId IdType="pubmed">27092775</ArticleId></ArticleIdList></Reference><Reference><Citation>Freites-Martinez A., Santana N., Arias-Santiago S., Viera A. (2021). Using the Common Terminology criteria for adverse events (CTCAE – version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliográficas 112, 90–92. 10.1016/j.ad.2019.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ad.2019.05.009</ArticleId><ArticleId IdType="pubmed">32891586</ArticleId></ArticleIdList></Reference><Reference><Citation>
Global Initiative for Chronic Obstructive Lung Disease (2023). Global strategy for prevention, diagnosis and management of COPD: 2023 report. Bethesda. Glob. Initiative Chronic Obstr. Lung Dis. - GOLD. Available at: https://goldcopd.org/(Accessed October 25, 2023).</Citation></Reference><Reference><Citation>
Global Initiative for Chronic Obstructive Lung Disease - GOLD (2020). Global strategy for prevention, diagnosis and management of COPD: 2020 report. Bethesda. Glob. Initiative Chronic Obstr. Lung Dis. - GOLD. Available at: https://goldcopd.org/(Accessed October 31, 2023).</Citation></Reference><Reference><Citation>Graham B. L., Steenbruggen I., Miller M. R., Barjaktarevic I. Z., Cooper B. G., Hall G. L., et al. (2019). Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am. J. Respir. Crit. Care Med. 200, e70–e88. 10.1164/rccm.201908-1590ST</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201908-1590ST</ArticleId><ArticleId IdType="pmc">PMC6794117</ArticleId><ArticleId IdType="pubmed">31613151</ArticleId></ArticleIdList></Reference><Reference><Citation>Han M. K., Agusti A., Celli B. R., Criner G. J., Halpin D. M. G., Roche N., et al. (2021). From GOLD 0 to pre-COPD. Am. J. Respir. Crit. Care Med. 203, 414–423. 10.1164/rccm.202008-3328PP</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202008-3328PP</ArticleId><ArticleId IdType="pmc">PMC7885837</ArticleId><ArticleId IdType="pubmed">33211970</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg J. C., Timens W. (2009). The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol. 4, 435–459. 10.1146/annurev.pathol.4.110807.092145</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pathol.4.110807.092145</ArticleId><ArticleId IdType="pubmed">18954287</ArticleId></ArticleIdList></Reference><Reference><Citation>Iheanacho I., Zhang S., King D., Rizzo M., Ismaila A. S. (2020). Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int. J. Chron. Obstruct Pulmon Dis. 15, 439–460. 10.2147/COPD.S234942</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S234942</ArticleId><ArticleId IdType="pmc">PMC7049777</ArticleId><ArticleId IdType="pubmed">32161455</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M., Lu C., Zhang C., Yang J., Tan Y., Lu A., et al. (2012). Syndrome differentiation in modern research of traditional Chinese medicine. J. Ethnopharmacol. 140, 634–642. 10.1016/j.jep.2012.01.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2012.01.033</ArticleId><ArticleId IdType="pubmed">22322251</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones P. W., Harding G., Berry P., Wiklund I., Chen W.-H., Kline Leidy N. (2009). Development and first validation of the COPD assessment test. Eur. Respir. J. 34, 648–654. 10.1183/09031936.00102509</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00102509</ArticleId><ArticleId IdType="pubmed">19720809</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones P. W., Quirk F. H., Baveystock C. M., Littlejohns P. (1992). A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am. Rev. Respir. Dis. 145, 1321–1327. 10.1164/ajrccm/145.6.1321</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm/145.6.1321</ArticleId><ArticleId IdType="pubmed">1595997</ArticleId></ArticleIdList></Reference><Reference><Citation>Julious S. A. (2005). Sample size of 12 per group rule of thumb for a pilot study. Pharm. Stat. 4, 287–291. 10.1002/pst.185</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pst.185</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung K.-H., Haam K.-K., Park S., Kim Y., Lee S. R., Lee G., et al. (2013). The standardized herbal formula, PM014, ameliorated cigarette smoke-induced lung inflammation in a murine model of chronic obstructive pulmonary disease. BMC Complement. Altern. Med. 13, 219. 10.1186/1472-6882-13-219</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6882-13-219</ArticleId><ArticleId IdType="pmc">PMC3847199</ArticleId><ArticleId IdType="pubmed">24010767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S.-W., Kim K.-I., Bu Y., Lee B.-J., Jung H.-J. (2022). Therapeutic potential of chungsangboha-tang for the treatment of asthma: a review of preclinical and clinical studies. J. Clin. Med. 11, 4035. 10.3390/jcm11144035</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11144035</ArticleId><ArticleId IdType="pmc">PMC9320585</ArticleId><ArticleId IdType="pubmed">35887796</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Oh J., Kim Y.-I., Ban H.-J., Kwon Y.-S., Oh I.-J., et al. (2013). Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses. BMC Pulm. Med. 13, 35. 10.1186/1471-2466-13-35</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2466-13-35</ArticleId><ArticleId IdType="pmc">PMC3680333</ArticleId><ArticleId IdType="pubmed">23731868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon S. S. C., Canavan J. L., Jones S. E., Nolan C. M., Clark A. L., Dickson M. J., et al. (2014). Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir. Med. 2, 195–203. 10.1016/S2213-2600(14)70001-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(14)70001-3</ArticleId><ArticleId IdType="pubmed">24621681</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lee B.-J., Jung H.-J., Choi J.-Y., Kang W., Jung S.-K. (2012a). Preliminary study to develop a Korean oriental medical assessment tool for syndrome differentiation of chronic obstructive pulmonary disease. J. Korean Med.
33, 82–94. Available at: https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001702026 (Accessed October 31, 2023).</Citation></Reference><Reference><Citation>Lee H., Kim Y., Kim H. J., Park S., Jang Y. P., Jung S., et al. (2012b). Herbal formula, PM014, attenuates lung inflammation in a murine model of chronic obstructive pulmonary disease. Evid. Based Complement. Altern. Med. 2012, 769830. 10.1155/2012/769830</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/769830</ArticleId><ArticleId IdType="pmc">PMC3384970</ArticleId><ArticleId IdType="pubmed">22778777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.-Y., Lee G.-H., Kim H.-K., Chae H.-J. (2019). Platycodi Radix and its active compounds ameliorate against house dust mite-induced allergic airway inflammation and ER stress and ROS by enhancing anti-oxidation. Food Chem. Toxicol. 123, 412–423. 10.1016/j.fct.2018.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2018.11.001</ArticleId><ArticleId IdType="pubmed">30399386</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lee S., Lee J. S., Song J. W., Choi C. M., Shim T. S., Kim T. B., et al.  (2010). Validation of the Korean version of chronic obstructive pulmonary disease assessment test (CAT) and dyspnea-12 questionnaire. Tuberc. Respir. Dis.
69, 171–176. Available at: https://e-trd.org/journal/view.php?number=747 (Accessed October 27, 2023).</Citation></Reference><Reference><Citation>Lee Y.-C., Lee J.-C., Seo Y.-B., Kook Y.-B. (2005). Liriopis tuber inhibit OVA-induced airway inflammation and bronchial hyperresponsiveness in murine model of asthma. J. Ethnopharmacol. 101, 144–152. 10.1016/j.jep.2005.04.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2005.04.030</ArticleId><ArticleId IdType="pubmed">15982838</ArticleId></ArticleIdList></Reference><Reference><Citation>López-Campos J. L., Tan W., Soriano J. B. (2016). Global burden of COPD. Respirology 21, 14–23. 10.1111/resp.12660</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/resp.12660</ArticleId><ArticleId IdType="pubmed">26494423</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu Y. R., Lee S.-W., Kim S.-Y., Han H.-B., Yang W.-K., Kim S.-H., et al. (2022). Herbal medicines for the treatment of chronic obstructive airway diseases (asthma or chronic obstructive pulmonary disease): a prospective observational study. Evid. Based Complement. Altern. Med. 2022, 3485757. 10.1155/2022/3485757</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/3485757</ArticleId><ArticleId IdType="pmc">PMC9168097</ArticleId><ArticleId IdType="pubmed">35677382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mador M. J., Kufel T. J. (1992). Reproducibility of visual analog scale measurements of dyspnea in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 146, 82–87. 10.1164/ajrccm/146.1.82</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm/146.1.82</ArticleId><ArticleId IdType="pubmed">1626820</ArticleId></ArticleIdList></Reference><Reference><Citation>Meek P. M. (2004). Measurement of dyspnea in chronic obstructive pulmonary disease: what is the tool telling you? Chron. Respir. Dis. 1, 29–37. 10.1191/1479972304cd008ra</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/1479972304cd008ra</ArticleId><ArticleId IdType="pubmed">16281665</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ministry of Food and Drug Safety (2024). Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=200002258aupdateTs2024-07-01%2015:25:08.0b (Accessed August 1, 2024).</Citation></Reference><Reference><Citation>Miravitlles M., Ribera A. (2017). Understanding the impact of symptoms on the burden of COPD. Respir. Res. 18, 67. 10.1186/s12931-017-0548-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-017-0548-3</ArticleId><ArticleId IdType="pmc">PMC5399825</ArticleId><ArticleId IdType="pubmed">28431503</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Donnell D. E., Banzett R. B., Carrieri-Kohlman V., Casaburi R., Davenport P. W., Gandevia S. C., et al. (2007). Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc. Am. Thorac. Soc. 4, 145–168. 10.1513/pats.200611-159CC</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/pats.200611-159CC</ArticleId><ArticleId IdType="pubmed">17494725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong K.-C. (2021). Evaluating dyspnoea in chronic obstructive pulmonary disease. Precis. Future Med. 5, 62–68. 10.23838/pfm.2020.00212</Citation><ArticleIdList><ArticleId IdType="doi">10.23838/pfm.2020.00212</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y.-B., Rhee C. K., Yoon H. K., Oh Y.-M., Lim S. Y., Lee J. H., et al. (2018). Revised (2018) COPD clinical practice guideline of the Korean Academy of Tuberculosis and respiratory disease: a summary. Tuberc. Respir. Dis. Seoul. 81, 261–273. 10.4046/trd.2018.0029</Citation><ArticleIdList><ArticleId IdType="doi">10.4046/trd.2018.0029</ArticleId><ArticleId IdType="pmc">PMC6148094</ArticleId><ArticleId IdType="pubmed">29926554</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan Y., Li L., Yin Z., Chen S., Yi J., Lang J., et al. (2021). Bulbus Fritillariae cirrhosae as a respiratory medicine: is there a potential drug in the treatment of COVID-19? Front. Pharmacol. 12, 784335. 10.3389/fphar.2021.784335</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.784335</ArticleId><ArticleId IdType="pmc">PMC8811224</ArticleId><ArticleId IdType="pubmed">35126123</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman Md. M., Bibi S., Rahaman Md. S., Rahman F., Islam F., Khan M. S., et al. (2022). Natural therapeutics and nutraceuticals for lung diseases: traditional significance, phytochemistry, and pharmacology. Biomed. and Pharmacother. 150, 113041. 10.1016/j.biopha.2022.113041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113041</ArticleId><ArticleId IdType="pubmed">35658211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ries A. L. (2005). Minimally clinically important difference for the UCSD shortness of breath questionnaire, Borg scale, and visual analog scale. COPD 2, 105–110. 10.1081/copd-200050655</Citation><ArticleIdList><ArticleId IdType="doi">10.1081/copd-200050655</ArticleId><ArticleId IdType="pubmed">17136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurgeirsdottir J., Halldorsdottir S., Arnardottir R. H., Gudmundsson G., Bjornsson E. H. (2019). COPD patients’ experiences, self-reported needs, and needs-driven strategies to cope with self-management. Int. J. Chron. Obstruct Pulmon Dis. 14, 1033–1043. 10.2147/COPD.S201068</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S201068</ArticleId><ArticleId IdType="pmc">PMC6529673</ArticleId><ArticleId IdType="pubmed">31190788</ArticleId></ArticleIdList></Reference><Reference><Citation>Son M.-K., Lee Y.-W., Jung H.-Y., Yi S.-W., Lee K.-H., Kim S.-U., et al. (2008). Comparison of the Naranjo and WHO-Uppsala Monitoring Centre criteria for causality assessment of adverse drug reactions. Korean J. Med. 74, 181–187.</Citation></Reference><Reference><Citation>Wang H., Naghavi M., Allen C., Barber R. M., Bhutta Z. A., Carter A., et al. (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1459–1544. 10.1016/S0140-6736(16)31012-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31012-1</ArticleId><ArticleId IdType="pmc">PMC5388903</ArticleId><ArticleId IdType="pubmed">27733281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Ma H., Shi Y., Ni H., Qin C., Ji C. (2024). Single-arm clinical trials: design, ethics, principles. BMJ Support. and Palliat. Care–2024-004984. 10.1136/spcare-2024-004984</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/spcare-2024-004984</ArticleId><ArticleId IdType="pubmed">38834238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y., Li Y., Wang S., Xiang Z., Li X., Wang Q., et al. (2023). Phytochemistry and pharmacology of Armeniacae semen Amarum: a review. J. Ethnopharmacol. 308, 116265. 10.1016/j.jep.2023.116265</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2023.116265</ArticleId><ArticleId IdType="pubmed">36806484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>